论文部分内容阅读
目的探讨氯雷他定应用于咳嗽变异性哮喘患儿中的效果。方法 88例咳嗽变异性哮喘患儿以随机数字表分为研究组与对照组,每组44例。两组均采取常规抗感染、吸氧、解痉平喘等对症治疗,在此基础上,对照组口服酮替芬治疗,研究组口服氯雷他定治疗。观察对比两组临床疗效、临床症状的改善时间及不良反应情况。结果研究组患儿总有效率为93.18%,显著高于对照组75.00%,差异具有统计学意义(P<0.05)。研究组患儿临床症状消失时间为(4.52±1.52)d,明显短于对照组的(6.55±1.25)d,差异具有统计学意义(t=6.842,P<0.05)。研究组与对照组不良反应发生率(2.27%VS 0)比较差异无统计学意义(χ2=1.011,P>0.05)。结论氯雷他定应用于咳嗽变异性哮喘患儿中具有显著的效果,可以快速改善临床症状,安全可靠,适于推广。
Objective To investigate the efficacy of loratadine in children with cough variant asthma. Methods Eighty - eight children with cough variant asthma were divided into study group and control group by random number table, with 44 cases in each group. Both groups took conventional anti-infective, oxygen, antispasmodic and asthma symptomatic treatment, on this basis, the control group oral ketotifen treatment, the study group oral loratadine treatment. Observed and compared the clinical efficacy of two groups, the improvement of clinical symptoms and adverse reactions. Results The total effective rate in study group was 93.18%, which was significantly higher than that in control group (75.00%), the difference was statistically significant (P <0.05). The disappearance time of clinical symptoms in study group was (4.52 ± 1.52) d, which was significantly shorter than that in control group (6.55 ± 1.25) d, the difference was statistically significant (t = 6.842, P <0.05). There was no significant difference in the incidence of adverse reactions between the study group and the control group (2.27% vs 0) (χ2 = 1.011, P> 0.05). Conclusion The application of loratadine in children with cough variant asthma has a significant effect, can quickly improve clinical symptoms, safe and reliable, suitable for promotion.